Scynexis (SCYX) Depreciation & Amortization (CF) (2021 - 2023)
Scynexis' (SCYX) quarterly Depreciation & Amortization (CF) came in at $129000.0 in Q4 2023, down 16.77% on a YoY basis from $155000.0 in Q4 2022, and down 12.24% quarter-over-quarter from $147000.0 in Q3 2023.
Powered by 
Analysis
Scynexis (SCYX) Depreciation & Amortization (CF) (2021 - 2023) Analysis & Trends
Scynexis (SCYX) has reported Depreciation & Amortization (CF) for 3 consecutive years, with $129000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Depreciation & Amortization (CF) fell 16.77% year-over-year to $129000.0; the trailing twelve-month figure through Sep 2024 stood at $129000.0 (down 78.71% YoY), and the FY2023 full-year result was $580000.0, down 4.29% from the prior year.
- Depreciation & Amortization (CF) fell to $129000.0 in Q4 2023 per SCYX's latest filing, from $147000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $246000.0 in Q4 2021 and bottomed at $27000.0 in Q1 2021.
- Historically, Depreciation & Amortization (CF) has averaged $130416.7 across 3 years, with a median of $148500.0 in 2022.
- The widest YoY moves for Depreciation & Amortization (CF): up 474.07% in 2022, down 36.99% in 2022.
- Over 3 years, Depreciation & Amortization (CF) stood at $246000.0 in 2021, then tumbled by 36.99% to $155000.0 in 2022, then declined by 16.77% to $129000.0 in 2023.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $129000.0, $147000.0, and $153000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.11 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 56.50 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 123.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 236.10 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 600,000.00 |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 129,000.00 |
| Sep 30, 2023 | 147,000.00 |
| Jun 30, 2023 | 153,000.00 |
| Mar 31, 2023 | 151,000.00 |
| Dec 31, 2022 | 155,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 146,000.00 |
| Mar 31, 2022 | 155,000.00 |
| Dec 31, 2021 | 246,000.00 |
| Sep 30, 2021 | 48,000.00 |
| Jun 30, 2021 | 58,000.00 |
| Mar 31, 2021 | 27,000.00 |